StemCell Therapy

DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Mycosis Fungoides (MF) and Szary Syndrome (SS) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) market. A detailed picture of the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) pipeline landscape is provided, which includes the disease overview and Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) treatment guidelines.

The assessment part of the report embraces in-depth Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) commercial assessment and clinical assessment of the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

Scope of the Report

Key Topics Covered

1. Report Introduction

2. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS)

2.1. Overview

2.2. History

2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Diagnosis

2.6.1. Diagnostic Guidelines

3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Current Treatment Patterns

3.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Treatment Guidelines

4. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Late Stage Products (Phase-III)

7. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Discontinued Products

13. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Key Companies

15. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Unmet Needs

18. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Future Perspectives

19. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nfdd1l

Follow this link:
Relapsed or Refractory Mycosis Fungoides (MF) and Sezary Syndrome (SS) - Global Industry Assessment and Pipeline Insights, 2020 -...

This entry was posted on July 2, 2020 at 1:45 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |